| Literature DB >> 28412932 |
Amelework Yilema1, Feleke Moges2, Sisay Tadele2, Mengistu Endris2, Afework Kassu2, Wondwossen Abebe2, Getnet Ayalew2.
Abstract
BACKGROUND: Enterococci become clinically important especially in immune compromised patients and important causes of nosocomial infections. Data on the prevalence, antimicrobial susceptibility patterns and associated factors of enterococci are scarce in Ethiopia.Entities:
Keywords: Antimicrobial susceptibility; Associated factors; Enterococci
Mesh:
Substances:
Year: 2017 PMID: 28412932 PMCID: PMC5392940 DOI: 10.1186/s12879-017-2363-3
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Socio-demographic characteristics of the study participants and prevalence of enterococci infection at the UoGTH, February 28, 2014 to May 1, 2014.
| Socio-demographics | Frequency (%) | Enterococci infection | |
|---|---|---|---|
| Present no. (%) | Absent no. (%) | ||
| Sex | |||
| Female | 176 (45.7) | 10 (5.7) | 166 (94.3) |
| Male | 209 (54.3) | 14 (6.7) | 195 (93.3) |
| Age (years) | |||
| <5 | 123 (31.9) | 12 (9.8) | 111 (90.2) |
| 5–14 | 36 (9.4) | 1 (2.8) | 35 (97.2) |
| 15–30 | 108 (28) | 3 (2.8) | 105 (97.2) |
| 31–50 | 83 (21.6) | 3 (3.6) | 80 (96.4) |
| >50 | 35 (9.1) | 5 (14.3) | 30 (85.7) |
| Residence | |||
| Rural | 169 (44.0) | 13 (7.7) | 156 (92.3) |
| Urban | 216 (56.0) | 11 (5.1) | 205 (94.9) |
| Patient setting | |||
| Out-patient | 92 (23.9) | 88 (95.6) | |
| In-patient | 293 (76.1) | 20 (6.8) | 273 (93.2) |
| Educational status | |||
| Illiterate | 180 (46.8) | 11 (6.1) | 169 (93.9) |
| Literate | 205 (53.2) | 13 (6.3) | 192 (93.7) |
| Total | 385 (100.0) | 24 (6.2) | 361 (93.8) |
Distribution of enterococci in different clinical samples (n = 24) at the UoGTH, February 28, 2014 to May 1, 2014
| Type of sample | Frequency (%) |
|---|---|
| Abdominal abscess | 1 (4.2) |
| Ascetic | 1 (4.2) |
| Blood | 5 (20.8) |
| Ear discharge | 1 (4.2) |
| Urine | 10 (41.6) |
| Wound | 6 (25.0) |
| Total | 24 (100.0) |
Antimicrobial susceptibility patterns of enterococci (n = 24) at the UoGTH, February 28, 2014 to May 1, 2014
| Antimicrobial discs | Susceptible no. (%) | Resistant count (%) |
|---|---|---|
| Amoxicillin/clavuanic acid | 8/24 (33.3) | 16/24 (66.7) |
| Ampicillin | 8/24 (33.3) | 16/24 (66.7) |
| Chloramphenicol | 7/24 (29.2) | 17/24 (70.8) |
| Ciprofloxacin | 7/24 (29.2) | 17/24 (70.8) |
| Doxycycline | 6/19 (32) | 13/19 (68) |
| Erythromycin | 5/14 (36) | 9/14 (64) |
| Penicillin | 8/24 (33.3) | 16/24 (66.7) |
| Tetracycline | 6/19 (32) | 13/19 (68) |
| Vancomycin | 14/24 (58.3) | 1024 (41.7) |
Profile of multidrug resistant enterococci isolates at the UoGTH, February 28, 2014 to May 1, 2014
| Resistance rate | Combination of antibiotics | No. (%) of isolates tested |
|---|---|---|
| R5 | TE, E, DOXY, CIP, CAF | 1 |
| R5 | TE, E, DOXY, CIP, VAN | 1 |
| R6 | E, CIP, CAF, AMP, P, AMC | 1 |
| R7 | TE, E, CIP, CAF, AMP, P, AMC | 1 |
| R8 | TE, E, DOXY, CIP, CAF, AMP, P, AMC | 5 |
| R8 | TE, E, DOXY, CAF, AMP, P, AMC, VAN | 1 |
| R9 | TE, E, DOXY, CIP, CAF, AMP, P, AMC, VAN | 8 |
| Total | 18 |
Key; E erythromycin, TE tetracycline, AMP ampicillin, P penicillin, AMC amoxicillin/clavuanic acid, CAF chloramphenicol, CIP ciprofloxacin, DOXY doxycycline, VAN Vancomycin, R Resistance.R2-R9 Number of antibiotics resistance from 2 to 9, respectively. MDR organisms resistant to >2 antibiotics
Bivariate analysis of enterococci infections at the UoGTH, February 28, 2014 to May 1, 2014
| Characteristics | Total | Enterococci infection | COR (95% CI) |
| |
|---|---|---|---|---|---|
| Presence | Absence | ||||
| Total | 385 (100%) | 24 (6.2%) | 361 (93.8%) | ||
| Sex | |||||
| Female | 176 | 10 (5.7) | 166 (94.3) | 1.19 (0.51–2.75) | 0.68 |
| Male | 209 | 14 (6.7) | 195 (93.3) | 1.00 | |
| Age | 0.06 | ||||
| <5 | 123 | 12 (9.8) | 111 (90.2) | 0.26 (0.03–2.10) | 0.21 |
| 5–14 | 36 | 1 (2.8) | 35 (97.2) | 0.26 (0.07–0.96) | 0.04 |
| 15–30 | 108 | 3 (2.8) | 105 (97.2) | 0.35 (0.10–1.27) | 0.11 |
| 31–50 | 83 | 3 (3.6) | 80 (96.4) | 1.54 (0.50–4.72) | 0.45 |
| >50 | 35 | 5 (14.3) | 30 (85.7) | 1.00 | |
| Hospital stay (hours) | |||||
| <48 | 353 | 7 (2) | 346 (98) | 1.00 | |
| ≥48 | 32 | 17 (53) | 15 (47) | 56.02 (18.32–178.39) | 0.00 |
| HIV | |||||
| Negative | 367 | 22 (6) | 345 (94) | 1.00 | |
| Positive | 18 | 2 (0.1) | 16 (99.9) | 1.96 (0.00–9.79) | 0.39 |
| CD4 counta | |||||
| <200 | 6 | 0 (0.0) | 6 (100) | 0.00 (0.00–9.76) | |
| >200 | 12 | 2 (16.7) | 10 (83.3) | 1.00 | 0.52 |
| HAARTa | |||||
| Pre | 9 | 2 (22.2) | 7 (87.8) | 1.00 | |
| On | 9 | 0 (0.0) | 9 (100) | 0.00 (0.00–4.38) | 0.47 |
| WHO stagea | 1.00 | ||||
| I | 5 | 2 (40) | 3 (60) | 1.00 | |
| II | 1 | 0 (0.0) | 1 (100) | 0.00 (0.00–60.98) | 1.00 |
| III | 6 | 0 (0.0) | 6 (100) | 0.00 (0.00–3.71) | 0.18 |
| IV | 6 | 0 (0.0) | 6 (100) | 0.00 (0.00–3.71) | 0.18 |
| History of: | |||||
| Animal contact | 111 | 10 (9) | 101 (90) | 1.84 (0.73–4.58) | 0.15 |
| Antibiotics usage | 54 | 14 (25.9) | 40 (74.1) | 11.24 (4.34–29.47) | 0.00 |
| Cancer | 3 | 1 (33.3) | 2 (66.7) | 7.80 (0.00–116.25) | 0.18 |
| Catheterization | 17 | 11 (64.7) | 6 (35.3) | 50.06 (14.24–184.31) | 0.00 |
| Diabetics | 9 | 0 (0.0) | 9 (100) | 0.00 (0.00–9.28) | 1.00 |
| Cotrimoxazole prophylaxisa | 36 | 2 (5.6) | 34 (94.4) | 0.87 (0.20 - 3.88) | 1.00 |
| Hospitalization | 40 | 11 (27.5) | 29 (72.5) | 9.69 (3.66–25.68) | 0.00 |
| Immunosuppressive usage | 51 | 3 (5.9) | 48 (94.1) | 0.93 (0.21–3.47) | 1.00 |
| Laboratory confirmed Bacterial infection | 10 | 3 (30) | 7 (70) | 7.22 (1.36–34.43) | 0.02 |
| Prosthetic device usage | 10 | 1 (10) | 9 (90) | 1.70 (0.21–14.01) | 0.48 |
| Surgery | 6 | 0 (0.0) | 6 (100) | 0.00 (0.00–14.88) | 1.00 |
| UTI | 55 | 2 (3.6) | 53 (96.4) | 0.53 (0.08–2.42) | 0.55 |
aOnly for HIV positives
Multivariable analysis of enterococci infections at the UoGTH, February 28, 2014 to May 1, 2014
| Factors | AOR (95% C.I) |
|
|---|---|---|
| Age | ||
| <5 | 1.67 (0.22–12.56) | 0.62 |
| 5–14 | 3.51 (0.20–60.29) | 0.39 |
| 15–30 | 0.66 (0.07–6.04) | 0.71 |
| 31–50 | 0.33 (0.34–3.08) | 0.33 |
| >50 | 1.00 | |
| Hospital stay ≥48 h | 63.31 (16.09–249.07) | 0.00 |
| History of: | ||
| Animal contact | 1.80 (0.33–9.808) | 0.50 |
| Antibiotic usage | 9.13 (2.01–41.51) | 0.00 |
| Cancer | 0.26 (0.01–9.73) | 0.47 |
| Urinary catheterization | 8.80 (1.70–45.64) | 0.01 |
| Laboratory confirmed bacterial infection | 0.24 (0.01–5.79) | 0.38 |
| Hospitalization | 2.10 (0.26–16.57) | 0.49 |